Homepage>Company>Media>Pharma News>2021>JCR Pharmaceuticals : US FDA grants Fast Track Designation for JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPSI)
JCR Pharmaceuticals : US FDA grants Fast Track Designation for JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPSI)